Phase 3 Study to Compare the Efficacy and Safety of JTZ-951 with Darbepoetin Alfa in Anemic Patients with Chronic Kidney Disease Not Requiring Dialysis (Anemia Correction / Switch / Maintenance Study).
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Dec 2018
At a glance
- Drugs JTZ 951 (Primary) ; Darbepoetin alfa
- Indications Anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Anemia Correction / Switch / Maintenance Study
- Sponsors Japan Tobacco
- 28 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Feb 2018 New trial record